Docetaxel improved DFS when used sequentially in early stage breast cancer

October 2008
Hem/Onc Today;10/25/2008, Vol. 9 Issue 19, p18
The article elaborates a research about docetaxel conducted by Francesco Cognetti of the Instituto Oncologic Regina Elena in Rome, Italy. Findings revealed that the addition of docetaxel to a sequential regimen of epirubicin and Cyclophosphamide Methotrexate Fluorouracil (CMF) chemotherapy made a positive impact on the survival in patients with node-positive, early-stage breast cancer.


Related Articles

  • Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer. Vassey, P.A.; Roche, H.; Bisset, D.; Terret, C.; Vernillet, L.; Riva, A.; Ramazeilles, C.; Azli, N.; Kaye, S.B.; Twelves, C.J. // British Journal of Cancer;11/01/2002, Vol. 87 Issue 10, p1072 

    Reports on the Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer. Determination of the maximum tolerated dose, dose-limiting toxicity and recommended dose of docetaxel; Pharmacokinetics of docetaxel.

  • Quality of Life of Patients with Metastatic Breast Cancer Treated with Epirubicin and Docetaxel. Korpela, Jaana; Mali, Pekka; Kaljonen, Anne; Salminen, Eeva // International Journal of Clinical Medicine;Jul2011, Vol. 2 Issue 3, p346 

    This phase II study assessed the clinical response and short-term quality of life of patients receiving first-line chemotherapy with epirubicin-docetaxel combination for metastatic breast cancer. Thirty-one breast cancer patients were treated with epirubicin (75 mg/m2 for 15 minutes) followed...

  • Study Finds Genetic Profiling Can Predict Breast Cancer Chemotherapy Response.  // Access;Aug2003, Vol. 17 Issue 7, p6 

    Presents a study on the ability of genetic profiling to predict chemotherapy docetaxel response of breast cancer patients in Houston, Texas. Determination of women not in need of chemotherapy; Capacity of physicians to prioritize breast cancer treatment strategies; Examination of pretreatment...

  • Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer. Toi, M; Bando, H; Horiguchi, S; Takada, M; Kataoka, A; Ueno, T; Saji, S; Muta, M; Funata, N // British Journal of Cancer;6/14/2004, Vol. 90 Issue 12, p2338 

    The combination effect of docetaxel and capecitabine on tumour response rate and survival was demonstrated recently in metastatic breast cancer patients. This combination was based on an experimental hypothesis that taxane can increase tumour sensitivity to the effect of capecitabine through the...

  • Systemic Taxotere Chemotherapy for Metastatic Tumor Pleurisy in Cats with Spontaneous Breast Cancer. Yakunina, M. N.; Treshalina, E. M. // Bulletin of Experimental Biology & Medicine;Mar2011, Vol. 150 Issue 5, p642 

    Systemic and intrapleural chemotherapy for metastatic tumor pleurisy was carried out in cats with breast carcinoma. The animals ( n=18) were divided into 2 groups. Cats of the systemic chemotherapy group received 3-6 courses of taxotere (30 mg/m; n=7) or 3 courses of taxotere (20 mg/m) in...

  • A phase II trial of docetaxel (Taxotere®) as second-line chemotherapy in patients with metastatic breast cancer. Baur, Martina; van Oosterom, Allan T.; Diéras, Véronique; Tubiana-Hulin, Michele; Coombes, R. Charles; Hatschek, Thomas; Murawsky, Michael; Klink-Alakl, May; Hudec, Marcus; Dittrich, Christian // Journal of Cancer Research & Clinical Oncology;Feb2008, Vol. 134 Issue 2, p125 

    The efficacy and tolerability of docetaxel 100 mg/m² every 3 weeks as second-line chemotherapy in patients with metastatic breast cancer was investigated. In addition, the efficacy of a 3-day prophylaxis against cumulative dose-related fluid retention was examined with methylprednisolone 32...

  • HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination. Tiezzi, Daniel G.; Andrade, Jurandyr M.; Ribeiro-Silva, Alfredo; Zola, Fábio E.; Marana, Heitor R.C.; Tiezzi, Marcelo G. // BMC Cancer;2007, Vol. 7, p36 

    Background: Neoadjuvant chemotherapy has been considered the standard care in locally advanced breast cancer. However, about 20% of the patients do not benefit from this clinical treatment and, predictive factors of response were not defined yet. This study was designed to evaluate the...

  • RESEARCH HIGHLIGHTS. Lobert, Sharon // Oncology Nursing Forum;Oct2002, Vol. 29 Issue 9, p1257 

    Presents research highlights from the 38th Annual Meeting of the American Society of Clinical Oncology held in Orlando, Florida from May 18 to 21, 2002. Research of the Breast Cancer International Research Group of Los Angeles, California on the benefits of docetaxel to patients with...

  • Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02-98 Randomized Trial. Francis, Prudence; Crown, John; Di Leo, Angelo; Buyse, Marc; Balil, Ana; Andersson, Michael; Nordenskjöld, Bo; Lang, Istvan; Jakesz, Raimund; Vorobiof, Daniel; Gutiérrez, Jorge; Van Hazel, Guy; Dolci, Stella; Jamin, Sophie; Bendahmane, Belguendouz; Gelber, Richard D.; Goldhirsch, Aron; Castiglione-Gertsch, Monica; Piccart-Gebhart, Martine // JNCI: Journal of the National Cancer Institute;1/16/2008, Vol. 100 Issue 2, p121 

    Background: Docetaxel is more effective than doxorubicin for patients with advanced breast cancer. The Breast International Group 02-98 randomized trial tested the effect of incorporating docetaxel into anthracycline-based adjuvant chemotherapy and compared sequential vs concurrent...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics